(VIANEWS) – TherapeuticsMD Shares Take 31.04% Drop Over 21 Sessions
TherapeuticsMD (NASDAQ: TXMD) shares experienced an astounding decline of 31.04% over 21 sessions from August 24th to September 8th, from EUR3.93 to EUR2.71, representing four consecutive days of losses. Meanwhile, the NASDAQ index dropped 0.09% to EUR13,200.23 during this same timeframe.
TherapeuticsMD’s closing price of EUR2.71 marks an 84.43% decline from its 52-week high of EUR10.18 and has given rise to serious concerns regarding both their prospects and overall market conditions.
Investors and analysts will closely follow TherapeuticsMD’s financial performance to assess how losses have altered its growth trajectory. Regaining and rebuilding investor trust will be essential in shaping its future course.
About TherapeuticsMD
TherapeuticsMD is an American pharmaceutical company specializing in prescription pharmaceutical products and prenatal vitamins licensed from Mayne Pharma under its own brands BocaGreenMD and vitaMedMD. Established in 2008 in Boca Raton, Florida, TherapeuticsMD distributes its products through wholesalers and retail pharmacy distributors nationwide.
Yearly Analysis
Based on available information, TherapeuticsMD appears to be trading below its 52-week low price, suggesting it could be undervalued and provide potential long-term investment opportunities for investors who believe in its long-term prospects.
However, sales growth forecast for the next two years is highly unpredictable; with negative growth rate of 97.1% this year and significant increases of 350% expected by next year – an indication of significant challenges faced by the company but an opportunity for significant future expansion.
TherapeuticsMD’s EBITDA value of 0.53 is positive, which can be taken as an indication of its financial health. Further investigation should be undertaken regarding this company’s profitability and other financial metrics.
TherapeuticsMD may present an attractive investment opportunity due to its undervalued stock price; however, investors should carefully examine its financials, growth prospects and any other relevant aspects before making their final investment decision. It would also be wise to conduct additional research and analysis in order to ascertain if TherapeuticsMD fits in their portfolio or not.
Technical Analysis
There’s nothing quite so satisfying as being part of something big and important – in other words, life! When I look around me these days I feel overwhelmed with so much stuff going on at once that sometimes all it takes to feel satisfied again is a quick trip out the front door! TherapeuticsMD Inc. (TMDD) has been struggling to sustain its stock price, with current trading volumes coming in at 80797 — 60.48% below its average volume of 20,396 and well under both 50-day and 200-day moving averages of EUR4.00 and EUR4.53, respectively. As well as weak technicals, this low volume may indicate lack of investor enthusiasm in buying it at this price level. Lack of buying support has contributed further to TMDD’s decline, and its volatility measures show this by having had negative amplitude of 3.25% for each of the last week, month, and quarter periods. Volatility reflects an uncertain market perception of TMDD’s stock. Furthermore, stochastic oscillator analysis suggests that its stock has recently been overbought (>=80). This may be an indicator that TMDD stock could be due for a correction. Overall, its technical picture shows weakness with low trading volume, no clear direction and an overbought condition. Investors may wish to take precaution before investing in TherapeuticsMD’s stock or wait for more favorable technical configuration before entering a position.
Quarter Analysis
TherapeuticsMD’s sales growth is currently negative, showing a drop of 97.6% during this quarter and 47.9% anticipated during its next one. Current growth estimates stand at 98% while next quarter projections indicate a 100.2% decrease.
However, it should be noted that this company has seen year-on-year quarterly revenue growth of 25.6% during their last twelve trailing months; with their current revenue sitting at 69.77M this could be seen as positive sign by investors as evidence of future expansion potential for this firm.
Overall, investors should take both current sales growth and future revenue growth potential into consideration when making decisions regarding TherapeuticsMD investments. It may be prudent to wait for more positive sales projections before considering investing in this company.
Equity Analysis
Based on the financial data available, TherapeuticsMD appears to be an profitable company with a high return on equity. Their trailing twelve month EPS figure of EUR3.23 indicates a decent profit has been generated over recent months while their PE ratio of 0.84 indicates undervaluation; purchasers investing relatively low amounts for every euro in annual earnings.
However, it should be noted that a return on equity of 1134.2% should raise concerns, as this indicates the company may be taking on too much risk to achieve its returns. It would be prudent for potential investors to conduct further investigation in order to ascertain if such levels of risk can be sustained over time.
Overall, TherapeuticsMD appears to be an impressive company with strong profitability and potentially undervalued stocks. Potential investors should exercise caution and conduct additional research prior to making any definitive investment decisions.
More news about TherapeuticsMD (TXMD).
